, the vaccine maker set to be acquired by
, says first-quarter earnings more than tripled while revenue advanced 15% from a year ago.
The announcement was devoid of drama because
MedImmune had preannounced its results on April 9.
At the same time, the quarterly report was short on details because AstraZeneca made a $15.6 billion
takeover bid for the company last week. As a consequence, MedImmune canceled its May 3 conference call with analysts to discuss the financial results.
For those still keeping score, MedImmune earned $160 million, or 66 cents a share, on revenue of $574.8 million for the three months ended March 31. For the same period last year, the Gaithersburg, Md., company earned $47 million, or 18 cents a share, on revenue of $498 million.
Worldwide sales of MedImmune's biggest product, Synagis, rose 9% year over year to $507 million. Synagis prevents respiratory syncytial virus, a dangerous lung disease in infants and young children. Most of its sales are recorded in the U.S.